One Amgen Center Drive
We are all different, yet we have this in common: our mission to serve patients. This sense of shared purpose is key to our becoming one of the world’s leading biotechnology companies. It guides us as we continue to launch new medicines and reach millions of patients worldwide.
We live the mission.
We win together.
We thrive on continual challenge.
Our team of 22,000+ scientists and professionals worldwide bring distinct perspectives and experiences to all we do. We leverage our global talent to achieve together—to research, manufacture and deliver ever-better products and greater depth to our mission.
At Amgen, there is a strong correlation between our high level of diversity and performance. Because addressing issues with a wider range of perspectives and approaches leads to more creative problem-solving. Together, we’re transforming the promise of science and biotechnology into therapies that have the power to restore health.
Connect with us to explore how you can Win, Live, and Thrive at Amgen.
2514 articles about Amgen
Amgen (NASDAQ:AMGN) will host a webcasted call at 1:00 p.m. PT on Thursday, February 22, 2024 to discuss Rare Disease, its newly added fourth pillar of growth, and provide insights on its rare disease strategy and opportunities, including marketed products and pipeline.
Amgen will present at the 34th Annual Oppenheimer Healthcare Life Sciences Conference at 12:00 p.m. ET on Wednesday, Feb. 14, 2024.
Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2023 versus comparable periods in 2022.
Phase I results published Monday suggest Amgen’s investigational weight-loss drug MariTide produces longer-lasting effects than GLP-1s currently on the market.
Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024, after the close of the U.S. financial markets.
Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from Iceland, Denmark, and the USA published a study in Nature Structural & Molecular Biology titled "Variant in the synaptonemal complex protein SYCE2 associates with pregnancy loss through effects on recombination".
The regulator concluded that Prolia (denosumab) increases the risk of severe hypocalcemia, which may result in hospitalization and could trigger life-threatening events or even lead to death.
Despite a decline in postings, most life science organizations are still actively recruiting, and more than a third predict their number of open roles will increase in 2024.
Amgen (NASDAQ:AMGN) will present at the 2024 J.P. Morgan Healthcare Conference at 9:00 a.m. PT on Monday, January 8, 2024.
Amgen announced that the U.S. Food and Drug Administration has completed its review of the company's supplemental New Drug Application seeking full approval of LUMAKRAS®.
The year may be coming to a close, but there's no holiday break for the FDA, which will release five regulatory verdicts over the next two weeks.
Amgen announced two changes to its senior leadership team in the areas of research and development and technology, underscoring the advancement of the company's robust pipeline and its commitment to ongoing scientific and technological innovation.
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Company's Biologics License Application (BLA) for tarlatamab.
Amgen announced that its Board of Directors declared a $2.25 per share dividend for the first quarter of 2024.
Amgen (NASDAQ:AMGN) today announced the presentation of new data from its blood cancer portfolio and pipeline at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from Dec. 9-12 in San Diego.
The pharma giant is paying $9 million upfront to Phenomic AI to develop targets for stroma-rich cancers, some of the hardest cancers to treat, utilizing its single-cell RNA computing platform.
While Amgen and Mirati are widely viewed as frontrunners to win the first front line approval, analysts—and competitors—say the field is still wide open.
Amgen will present at the Evercore ISI HealthCONx Conference at 9:10 a.m. EST on Wednesday, Nov. 29, 2023.
Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, announced that it will regain full development and commercial rights to bempikibart from Amgen.
Amgen (NASDAQ:AMGN) today announced new data reinforcing the safety and efficacy of Repatha® (evolocumab) from the FOURIER Open Label Extension (OLE) [FOURIER-OLE] trial at the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia.